AbbVie (ABBV) Change in Receivables (2012 - 2026)
AbbVie (ABBV) reported Change in Receivables of -$87.0 million for Q1 2026, down 105.88% year-over-year from $1.5 billion in Q1 2025, and up 46.3% quarter-over-quarter from -$162.0 million in Q4 2025.
AbbVie (ABBV) Change in Receivables (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Change in Receivables data on file, last reported at -$87.0 million in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$87.0 million, down 105.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$76.0 million (down 113.33% YoY), and the FY2025 annual result was $1.5 billion, up 819.81% from the prior year.
- Change in Receivables rose to -$87.0 million in Q1 2026 per ABBV's latest filing, from -$162.0 million in the prior quarter.
- Over five years, Change in Receivables peaked at $1.5 billion in Q1 2025 and troughed at -$387.0 million in Q4 2024.
- A 5-year average of $152.1 million and a median of $17.0 million in 2025 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 260.0% in 2024 and fell as far as 17100.0% in 2024.
- A 5-year view of Change in Receivables shows it stood at $416.0 million in 2022, then sank by 181.49% to -$339.0 million in 2023, then declined by 14.16% to -$387.0 million in 2024, then jumped by 58.14% to -$162.0 million in 2025, then jumped by 46.3% to -$87.0 million in 2026.
- Business Quant data shows ABBV's Change in Receivables at -$87.0 million in Q1 2026, -$162.0 million in Q4 2025, and $156.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 595.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -87.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.69 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -504.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.00 Mn |
| Mar 31, 2026 | -87.00 Mn |
| Dec 31, 2025 | -162.00 Mn |
| Dec 31, 2025 | -162.00 Mn |
| Sep 30, 2025 | 156.00 Mn |
| Sep 30, 2025 | 156.00 Mn |
| Jun 30, 2025 | 17.00 Mn |
| Jun 30, 2025 | 17.00 Mn |
| Mar 31, 2025 | 1.48 Bn |
| Mar 31, 2025 | 1.48 Bn |
| Dec 31, 2024 | -387.00 Mn |
| Dec 31, 2024 | -387.00 Mn |
| Sep 30, 2024 | -344.00 Mn |
| Sep 30, 2024 | -344.00 Mn |
| Jun 30, 2024 | -178.00 Mn |
| Jun 30, 2024 | -178.00 Mn |
| Mar 31, 2024 | 702.00 Mn |
| Mar 31, 2024 | 702.00 Mn |
| Dec 31, 2023 | -339.00 Mn |
| Dec 31, 2023 | -339.00 Mn |